Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?

Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?

Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches...

Full description

Bibliographic Details
Main Authors:	Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2023-12-01
Series:	Cancer Biology & Medicine
Subjects:	locally advanced non-small cell lung cancer (la-nsclc) radiotherapy immunotherapy new regimen challenges
Online Access:	https://www.cancerbiomed.org/content/20/12/1035

Similar Items

Radiotherapy and Immunotherapy in Lung Cancer
by: Kristin Hsieh, et al.
Published: (2023-06-01)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
by: Jian Qin, et al.
Published: (2023-05-01)

Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
by: Leilei Wu, et al.
Published: (2023-05-01)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
by: Chen Jie, et al.
Published: (2023-02-01)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024-02-01)

Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer
by: Kathleen M. Capaccione, et al.
Published: (2022-09-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01)

Stereotactic body radiotherapy in lung cancer: a contemporary review
by: Emese Csiki, et al.
Published: (2024-02-01)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
by: Xiaofei Zhang, et al.
Published: (2023-02-01)

A Brief Report on the Role of SPECT/TC in the Optimization of Radiotherapy Treatment with Radical Intent for Unresectable Stage III NSCLC
by: Jessica Imbrescia, et al.
Published: (2022-09-01)

Differences between Survival Rates and Patterns of Failure of Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma Who Received Single-Fraction Stereotactic Body Radiotherapy
by: Tyler V. Schrand, et al.
Published: (2024-02-01)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
by: Ou Yamaguchi, et al.
Published: (2019-04-01)

Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta‐analysis
by: Jiupeng Zhou, et al.
Published: (2022-11-01)

Combination of immunotherapy-radiotherapy in non-small cell lung cancer: Reality and perspective
by: Bouchra Amaoui, et al.
Published: (2021-12-01)

Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study
by: Benjamin Spieler, et al.
Published: (2022-05-01)

Salvage LATTICE radiotherapy for a growing tumour despite conventional radio chemotherapy treatment of lung cancer
by: Rémy Kinj, et al.
Published: (2023-03-01)

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
by: Judith Porte, et al.
Published: (2022-09-01)

Three Weekly Versus Weekly Cisplatin: Comparison of two Different Chemotherapy Protocols with Concurrent Radiotherapy in Locally Advanced Head and Neck Cancer
by: Sankalp Singh, et al.
Published: (2022-05-01)

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature
by: Alessio Bruni, et al.
Published: (2023-01-01)

Advances in Lung Cancer Imaging and Therapy
by: Egesta Lopci, et al.
Published: (2021-12-01)

Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer
by: Astrid Zedlitz Johansen, et al.
Published: (2022-05-01)

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review
by: Jason Liu, et al.
Published: (2023-09-01)

Effects of Radiotherapy and Chemotherapy on Platelet in Patients with Lung Cancer
by: Shanshan Tang, et al.
Published: (2023-11-01)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
by: Henrik Horndalsveen, et al.
Published: (2023-03-01)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
by: Shujie Zhou, et al.
Published: (2023-01-01)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
by: Thomas Le Roy, et al.
Published: (2023-09-01)

An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
by: Saurav Verma, et al.
Published: (2024-03-01)

Research Progress on Combination of Radiotherapy and Immunotherapy on Advanced Non-small Cell Lung Cancer with Negative Driver Genes
by: LI Peng, et al.
Published: (2023-09-01)

Metronomic chemotherapy regimens in oncology
by: M. Yu. Fedyanin, et al.
Published: (2016-04-01)

ON THE SELECTION OF DRUGS DOSAGE REGIMEN
by: E. N. Bochanova
Published: (2015-09-01)

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer
by: Claudio Marcelo Martin, et al.
Published: (2023-01-01)

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review
by: Massimiliano Cani, et al.
Published: (2022-12-01)

Real‐world survival outcomes of immunotherapy for advanced non‐small cell lung cancer: A single‐center retrospective review
by: Gopika Punchhi, et al.
Published: (2024-02-01)

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
by: Chengli Du, et al.
Published: (2023-12-01)

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience
by: Michael C. Tjong, et al.
Published: (2022-01-01)

Editorial: Factors that impact the survival of non-small cell lung cancer
by: Fiona Hegi-Johnson, et al.
Published: (2023-02-01)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
by: Zi‐Chao Zhou, et al.
Published: (2022-08-01)

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
by: Giuseppe Viscardi, et al.
Published: (2022-11-01)

A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer
by: Lydia Melissourgou-Syka, et al.
Published: (2023-11-01)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
by: Paolo Borghetti, et al.
Published: (2022-07-01)